PCSK9 Education and Research Forum was established by an international panel of researchers and clinicians to provide independent news, analysis and commentary on this rapidly evolving area of cholesterol management.
News
Post hoc analysis: alirocumab benefits HeFH and T3HLP patientsResults from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acidPCSK9 inhibitors are unlikely to contribute to mood disordersPCSK9 inhibitors may be effective treatment for PADPACMAN-AMI: new data on lesion-level effects of lipid loweringAT-TARGET-IT shows reduced CV risk with early PCSK9i in ACS
Editorial Board
Editors
Professor M. John Chapman BSc(Hons), PhD, DSc, EFESCResearch Professor, Medical Faculty of Sorbonne University and Director Emeritus of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpêtrière University Hospital, Paris, FranceView Biography and Disclosures »
Professor Henry Ginsberg MDIrving Professor of Medicine, Past Director, Irving Institute for Clinical and Translational Research, College of Physicians and Surgeons, Columbia University, New York, USAView Biography and Disclosures »
Assistant Editors
Dr Michel Farnier MD PhDClinician based at Point Medical, Dijon, FranceView Biography and Disclosures »
Professor Frederick J. Raal MBBCh, FRCP, FRCPC, FCP(SA), Cert Endo, MMED, PhDDirector, Carbohydrate & Lipid Metabolism Research UnitView Biography and Disclosures »
Professor Anthony Wierzbicki Consultant in Metabolic Medicine/Chemical PathologyView Biography and Disclosures »
